Emerson Chen nag-retweet
Pembro in “TMB high” (10+) cancers - paper published in Lancet Oncol. No difference in OS between TMB high and TMB low. Neverthelessless FDA approved. SMH. @OncoAlert
English
Emerson Chen
23 posts
Emerson Chen
@IamEmchee
GI oncologist and health services researcher at Oregon Health & Science University
Portland, OR Sumali Aralık 2014
98 Sinusundan120 Mga Tagasunod
Emerson Chen nag-retweet
Friendly reminder that surrogate endpoints like PFS only reduce study time by an average of 11 months - @IamEmchee, et al. 🙂 We shouldn’t proclaim new therapies as “new standard of care”, without showing OS or QOL benefit for patients. #ASCO2020 #asco20 jamanetwork.com/journals/jamai…
English
Critical Care and the COVID-19 Outbreak in Italy: Early Experience and Forecast ja.ma/2wTgyUH
English
Emerson Chen nag-retweet
Canada's Transparency With Clinical Trial Puts Pressure On U.S. FDA To Reveal More : Shots - Health News : NPR npr.org/sections/healt…
English
@MWFriedberg It’s been looked at in oncology drug trials. jamanetwork.com/journals/jamao…
English
Couldn’t agree more, would like to tell my patients how a new therapy will directly help them. “Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs” ja.ma/2nolHiy
English
@docamitgs @NDP1001 @nicole_rich8 Beautiul study, May report too, curious about if DAA reduces mortality but has similar recurrent HCC, then would receipt of DAA influence survival outcome of adjuvant/consolidation systemic treatment (if ongoing trials are +)? What’s the HR in usual survival curve/Cox regression?
English
Great question! 🤔 This is an area where we have limited data re: benefits and cost effectiveness of #HepatitisC treatment. We are not treating patients with active #HCC at our site but have an ongoing study collecting data to inform this question. @NDP1001 @nicole_rich8
Maria Varela@Maria_Var_Cal
Do you recommend DAA for patients with HCC under palliative treatment, also? TACE plus SOR plus REGO plus...
English
Wow amazing online course that changed how I think about oncology drugs, and completed just in time before my first day as faculty tomorrow @edxonline #mooc edx.org/course/the-fda…
English
Emerson Chen nag-retweet
I look forward to a response and hope Dr. @ScottGottliebMD will rectify his mistake & resign from his position at @Pfizer. It would send a strong message about the importance of integrity of current & former federal officials.
English
@docamitgs @AASLDtweets @renumathyd @nicole_rich8 @MichiganLiver @GABOUALFA @NDP1001 @kwburak @NancyReau @dhjutsw1 Current U.S. cancer drug approval process allows multiple phase 3 trials to be run. 1) See FDA letter: accessdata.fda.gov/drugsatfda_doc…. 2) See how fast drug trials can get required data in today’s age jamanetwork.com/journals/jamai….
English
This is now 2nd negative trial of IO in #HCC - Keynote 240 and now Checkmate 459. What will/should FDA do with PD1 inhibitor approval, while awaiting combo trial results?
@AASLDtweets @renumathyd @nicole_rich8 @MichiganLiver @GABOUALFA @NDP1001 @kwburak @NancyReau @dhjutsw1
English
Checkmate459 results announced: Nivolumab fails to improve overall survival in patients with #HCC versus Sorafenib (HR=0.85; 95% CI 0.72-1.02).
businesswire.com/news/home/2019…
@MichiganLiver @NDP1001 @nicole_rich8 @JuanAbraldes @GABOUALFA @renumathyd @AASLDtweets @ASCO
English
Health policy conundrum, 1) gets cancer drug approved faster but more uncertainty 2) might not get drug approved but more certainty of clinical benefit jamanetwork.com/journals/jamai…
Shaalan Beg MD MBA FASCO@ShaalanBeg
@GIcancerDoc @pashtoonkasi @aakonc @UqbaKhan @kmody29 @DrR_DUNNE @gabe_a_brooks @agrothey @utswcancer @ASCOPost great point.. raises the question, should one design a trial aimed at the 1) end point you can achieve or 2) the end point which is more meaningful?
English
I find the sicker treatment-refractory patient tend to be on left and the healthier adjuvant/first-line metastatic patient on the right.
Michael Fisch MD MPH@fischmd
@barttels2 @cordekroon @oncology_bg @ASCO @ecancer @QueensCRI @scottrberry @cpgYALE @yzafar @MartinStockler @Prof_IanD @NicoleKuderer @JackWestMD The bargain of accelerated approvals and the spectrum of patient viewpoints on this issue was described brilliantly by @VPrasadMDMPH at #ASCO19
English
Emerson Chen nag-retweet
Len Saltz @sloan_kettering listing no-value interventions in #colorectalcancer Anything to add or subtract? #ASCO19 #crcsm
Chicago, IL 🇺🇸 English
Emerson Chen nag-retweet
On interpreting #clinicaltrials: When you hear “A HR of __ & a __month diff in PFS,” consider what the control arm is. The interpretation of those #s differs if comparator is placebo/BSC or active control, & if active control, if new drug is an add on or replacement tx. #ASCO19
Chicago, IL 🇺🇸 English
Emerson Chen nag-retweet
Emerson Chen nag-retweet
In light of today’s #ASCO19 plenary, please read our latest @JAMAInternalMed paper on accelerated approval to understand this pathway’s trade offs. We even managed to sneak in a sentence about #olaratumab at the very last moment. jamanetwork.com/journals/jamai… #ASCOplenary #sarcoma
English
Emerson Chen nag-retweet
Emerson Chen nag-retweet
And here’s the story covered by @rrichardh in the NPR : npr.org/sections/healt…
English
Emerson Chen nag-retweet
The biggest honor, however, is to have 2 editorials accompany our paper. I always lamented @RichardLehman1 ‘s retiring from BMJ blogs without getting chance to read his comment on my work. But now he has written an editorial instead with @cpgYALE . jamanetwork.com/journals/jamai… 🙏
English